Hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
proved	proved	O	O	O	O
very	very	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
otherwise	otherwise	O	O	O	O
resistant	resistant	O	O	O	O
cardiac	cardiac	O	O	O	O
tachyarrhythmias	tachyarrhythmias	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
,	,	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
been	been	O	O	O	O
limited	limited	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
its	its	O	O	O	O
serious	serious	O	O	O	O
side-effects	side-effects	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
cholestatic	cholestatic	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
is	is	O	O	O	O
presented	presented	O	O	O	O
below	below	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
review	review	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
given	given	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
concluded	concluded	O	O	O	O
that	that	O	O	O	O
solid	solid	O	O	O	O
evidence	evidence	O	O	O	O
exists	exists	O	O	O	O
of	of	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
injury	injury	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
steatosis	steatosis	O	O	OTHERS	I
,	,	O	O	O	O
alterations	alterations	O	O	O	O
resembling	resembling	O	O	O	O
alcoholic	alcoholic	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
cholestatic	cholestatic	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
micronodular	micronodular	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
of	of	O	O	OTHERS	I
the	the	O	O	OTHERS	I
liver	liver	O	O	OTHERS	I
.	.	O	O	O	O

Patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
amiodarone	amiodarone	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
regularly	regularly	O	O	O	O
screened	screened	O	O	O	O
with	with	O	O	O	O
respect	respect	O	O	O	O
to	to	O	O	O	O
hepatic	hepatic	O	O	O	O
enzyme	enzyme	O	O	O	O
levels	levels	O	O	O	O
.	.	O	O	O	O

Therapy	therapy	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
discontinued	discontinued	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
suspicion	suspicion	O	O	O	O
of	of	O	O	O	O
cholestatic	cholestatic	O	O	OTHERS	I
injury	injury	O	O	OTHERS	I
or	or	O	O	O	O
hepatomegaly	hepatomegaly	O	DISEASE	OTHERS	I
.	.	O	O	O	O

